Patients with chronic myeloid leukemia (CML) treated with the tyrosine kinase inhibitor (TKI) imatinib have increased bone mineral density (BMD). [1] [2] [3] Considering that dasatinib and imatinib partly inhibit the same tyrosine kinases, similar effects on bone metabolism might be seen with the second-generation TKI dasatinib.
The skeleton is continuously remodeled throughout life and to maintain bone homeostasis the activity of bone-forming osteoblasts and bone-resorbing osteoclasts is tightly coupled. The increased BMD observed in imatinib-treated patients [1] [2] [3] can thus be due to diminished bone degradation or increased bone formation. Imatinib inhibits differentiation and activity of osteoclasts in vitro and in animals through the inhibition of colony-stimulating factor 1 receptor (CSF1R), and dasatinib seems to have similar effects on osteoclasts. [4] [5] [6] [7] The effects of imatinib on osteoblast differentiation are, however, less uniform. 7, 8 Whether the second-generation TKI dasatinib influences osteoblast proliferation and differentiation in vitro has not previously been reported. Bone morphogenetic proteins (BMPs) are important promoters of osteoblast differentiation and bone formation. 9 We therefore investigated the effects of dasatinib on BMP-induced in vitro osteoblast differentiation from human mesenchymal stem cells (hMSCs). The hMSCs (obtained from Lonza Inc., Walkersville, MD, USA) were collected from normal human bone marrow and tested for purity by flow cytometry (positive for CD105, CD166, CD29 and CD44, negative for CD14, CD34 and CD45) and for their ability to differentiate into osteogenic, chondrogenic and adipogenic lineages. The stem cells were treated with BMP-2 in the absence or presence of dasatinib at therapeutic concentrations (5-80 nM). Dasatinib inhibited proliferation of hMSCs measured by methyl-3 H-thymidine incorporation ( Figure 1a) . Further, we found that dasatinib dose dependently inhibited early osteoblast differentiation measured by reduced alkaline phosphatase (ALP) activity ( Figure 1b ) and terminal differentiation of osteoblasts measured by reduced mineralization (Figure 1c ). The relative mRNA expression levels of early (Runx2) and late (Osterix) osteoblast-specific transcription factors (Figures 1d and  e) were inhibited by dasatinib, supporting the results obtained in the functional assays. Thus, our study data suggest that dasatinib inhibits osteoblast differentiation in vitro.
Tyrosine kinase inhibitor therapy has changed the course of CML from being a fatal disease to becoming a chronic disorder in which the patients will be on treatment for decades. Bone is continuously remodeled to maintain bone quality, and the longterm consequences of TKI on bone turnover are unclear. A dual inhibitory effect of dasatinib on osteoclasts and osteoblasts leads to reduced bone turnover, and might in particular affect processes requiring increased bone formation and remodeling, such as fracture healing and bone growth during fetal life and adolescence. There are at present no clinical data available supporting that dasatinib leads to hampered fracture healing or bone growth, but indeed, there are reports indicating that imatinib might be less beneficial for bone health in these settings. 10 Further, hypophosphatemia has been observed in 11% of patients treated with dasatinib, 11 indicating that similar to imatinib, dasatinib seems to have effects on bone metabolism.
Besides inhibiting BCR-ABL, both imatinib and dasatinib inhibit the tyrosine kinases c-ABL, platelet-derived growth factor receptors (PDGFR)-a and -b, stem cell factor receptor (c-KIT), discoidin domain receptor family member 1 and CSF1R. 12 In addition, dasatinib inhibits other tyrosine kinases such as Src family kinases and ephrin/eph kinases. Signaling through c-Abl and ephB4 promotes osteoblast differentiation. [13] [14] [15] Thus, inhibition of these kinases by dasatinib would possibly lead to reduced osteoblast differentiation, in line with our observations presented here. In our experiments we used BMP-2 to promote differentiation, and c-Abl has been shown to contribute to BMP-stimulated osteoblast differentiation. 13 Thus, inhibition of c-Abl by dasatinib is likely to explain the inhibitory effect on differentiation in our experiments. c-Abl is reported not to influence proliferation of osteoblasts or precursor cells whereas, on the other hand, c-Src and PDGFR promote proliferation of osteoblast precursors and inhibit differentiation. 13, 16, 17 In our experimental system using BMP to promote differentiation, the positive effect of c-Abl on differentiation possibly overrides the inhibitory effect of c-Src and/or PDGFR. We therefore propose that the inhibitory effect on proliferation might be due to PDGFR inhibition (PDGF is present in serum, and the cells are cultured in media containing serum) or possibly due to c-Src inhibition, whereas the inhibitory effect on differentiation probably is mediated by c-Abl or ephB4 inhibition.
Owing to their inhibitory effects on osteoclasts, imatinib and dasatinib have been considered as potential agents in treatment of osteolysis 4, 6, 18 but the inhibitory effects of dasatinib on osteoblasts presented here may possibly limit the potential of TKIs in this therapeutic setting. Moreover, the consequences of long-term treatment with the second-generation TKI dasatinib on bone health need to be further addressed in human and animal studies. Special surveillance may be warranted when TKIs are used during periods of extra demand for bone formation, such as fracture healing and bone growth.
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The oncogenic fusion protein MOZ-TIF2 is one of several fusion products resulting from reciprocal chromosomal rearrangements in the MOZ/MYST3/KAT6A gene in acute myeloid leukemia. 1 Previous studies have shown that MOZ-TIF2 transforms haematopoietic progenitors 2,3 and induces acute myeloid leukemia in a murine bone marrow transplant model. 2, 4 MOZ-TIF2 induces widespread changes in histone acetylation, 3, 5 subverting the development of haematopoietic progenitors towards leukaemia. One mechanism critical to the leukaemogenic action of MOZ-TIF2 is its association with the lysine acetyltransferases CBP and p300. 3 This interaction requires a C-terminal activation domain (AD1) present in TIF2. 6, 7 The AD1 sequence forms an amphipathic a-helix that is conserved in proteins such as Ets2, E1A, p160s and IRFs, 6 and which docks with the SID (SRC1 interaction domain) of CBP/p300 to form a stable fourhelix bundle. 7 Mutations in the AD1 a-helix render MOZ-TIF2 incapable of transforming haematopoietic cells and unable to induce leukaemia in a mouse model, 2, 3 indicating that recruitment of CBP/p300 is essential for cell transformation. A consequence of this interaction is the strong depletion of intracellular levels of CBP and p300 via a proteasome-independent mechanism, accompanied by a loss of transcription at p53 and nuclear receptor target genes, including the RARb2 gene. 3, 5 However, the mechanism by which MOZ-TIF2 promotes depletion of cellular CBP/p300 is unknown.
As MOZ-TIF2 did not alter the levels of CBP mRNA as determined by qPCR experiments (data not shown), we investigated whether proteasome or specific protease activities might contribute to the downregulation of CBP/p300. Precedence for this was provided by a study showing that in neuronal cells, CBP is targeted for degradation by calpains and caspases at the onset of apoptosis. 8 In this study, we report that a specific inhibitor of calpains and cathepsins (N-acetyl-leucyl leucyl-methioninal; ALLM or CPI-2) can block MOZ-TIF2-mediated destruction of CBP/p300 and rescue its repressive effects on gene expression. Expression of MOZ-TIF2 in different cell lines results in depletion of CBP from PML bodies and a strong reduction in overall cellular levels of CBP protein. 3, 5 Failure to detect changes in the levels of CBP transcripts indicated that this was likely to be a posttranscriptional effect (data not shown). To explore the underlying mechanism, a stable cell line (U2Os-TRex) carrying an inducible MOZ-TIF2 expression vector 5 was cultured in the presence or absence of doxycycline and treated with a range of small molecule inhibitors of protease or proteasome activities. Western blot analysis on whole cell extracts revealed that, consistent with previous results, cells induced to express YFP-MOZ-TIF2 (Figure 1a ; Lane 2), (but not YFP or YFP-MOZ-TIF2 DAD1 3 ), showed a strong depletion of CBP and p300 proteins (top and middle panels), in contrast to control proteins such as a-tubulin or b-actin (lower panel). Treatment of cells with the proteasome inhibitors lactacystin (10 mM), MG132 (10 mM) or vehicle for 8 h failed to rescue CBP/p300 levels in YFP-MOZ-TIF2 expressing cells, and did not affect CBP levels in YFP-expressing cells under similar conditions (Figure 1a, lanes 3,4 and data not shown) . These results indicate that the observed reduction in cellular CBP is unlikely to involve proteasomal degradation. Similarly, treatment of cells with a caspase 6 inhibitor (10 mM z-VEID-fmk), which has been reported to inhibit CBP degradation in neuronal cells 8 did not alter the reduced levels of CBP protein observed after YFP-MOZ-TIF2 induction (data not shown). However, pre-treatment of cells with calpain inhibitor 2 (CPI-2; 2 mM) for 8 h before harvesting completely restored CBP and p300 to the levels observed in the controls (Figure 1a , lane 5), whereas vehicle had no significant effect (Figure 1a, lane2) . In contrast, expression of b-actin and a-tubulin proteins, which are not affected by MOZ-TIF2, was also unaffected by CPI-2 treatment (Figure 1a lower panel) . Indeed, CPI-2 did not alter the levels of CBP in mock-transfected HEK293 controls (Figure 1b) indicating that the rescue effect is dependent on MOZ-TIF2. These results implicate the protease targets of CPI-2 (such as calpains I and II and cathepsins) in the degradation of CBP/p300 induced by MOZ-TIF2.
CBP and other proteins associated with leukaemias are often found to localize to PML or nuclear bodies. Cells expressing MOZ-TIF2 display a loss of CBP staining in nuclear bodies. 3 We therefore assessed whether CPI-2 could restore the accumulation
